Key result
AngioVac device thrombectomy was utilized in a patient with right atrial catheter-associated thrombus and gastrointestinal bleed who had contraindications to other thrombectomy therapies.
Why the study?
Catheter-directed thrombectomy is a novel promising therapy with little published experience, particularly in high-risk patients needing intravascular material resection.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
AngioVac thrombectomy may be a feasible option for right atrial thrombus removal in patients with high bleeding risk where other therapies are contraindicated.
Catheter-directed thrombectomy is a novel promising therapy with little published experience. Previous reports have described it as a useful tool in high risk patients in need of intravascular material resection. Here we present a unique and never reported case of AngioVac device thrombectomy use in a patient with right atrial catheter-associated thrombus and gastrointestinal bleed that contraindicated other thrombectomy therapies due to severe anemia and high bleeding risk. A brief literature review about this therapy and its main outcomes is presented to contextualize the reader and contribute to academic knowledge.
No takes yet. Share an insight, caveat, or question.
Vera-Sarmiento et al. (2021) conducted a case report in Right atrial catheter-associated thrombus and gastrointestinal bleed (n=1). AngioVac device thrombectomy was evaluated. AngioVac device thrombectomy was utilized in a patient with right atrial catheter-associated thrombus and gastrointestinal bleed who had contraindications to other thrombectomy therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: